Stempeutics Research inks deal with Alkem Laboratories for osteoarthritis drug: 3 insights

Written by Shayna Korol | February 13, 2018 | Print  |

Stempeutics Research signed an outlicensing deal with Alkem Laboratories for the knee osteoarthritis therapy Stempeucel, according to Business Today.

Here are three things to know:

 

1. Stempeucel will undergo Phase 3 clinical trials in India. It is expected to be available on the market by 2020.

 

2. The outlicensing deal consists of upfront payment, royalties and regulatory- and sales-based milestone payments. Alkem will gain exclusive marketing rights for Stempeucel for osteoarthritis use in India after the approval process is completed.

 

3. Allogeneic stem cell therapy dominates the global stem cells market, with a share of almost 63 percent compared to the 37 percent share of the autologous market. The stem cell therapy market is expected to grow rapidly in India.

 

More articles on biologics:

Osiris names interim CEO welcomes new board member: 3 insights

U.S. Stem Cell reveals the factors driving company growth: 4 insights

Royal Biologics reveals Amnio-Maxx: 4 notes

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies here.

Top 40 Articles from the Past 6 Months